Preclinically, POLθ inhibitors, such as NVB or ART558, have demonstrated substantial benefits in HR-deficient models of breast and ovarian cancers, secondary to the synthetic lethality induced by combined loss of HR and MMEJ leading to accumulation of single-stranded DNA intermediates and non-functional RAD51 foci5,6. The gene discussed is RAD51; the disease is ovarian carcinoma.